A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Clinical trial NCT04636593 · UNKNOWN

Trial details

NCT number: NCT04636593
Sponsor: First People's Hospital of Hangzhou
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Stage III NSCLC EGFR Activating Mutation

Start date: 2020-08-01
Primary completion: 2021-12-31
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.